Healthcare
Live Price
Offline$9.16
-1.51% today
1Y Change
+70.50%
Window
Jun 23, 2025 → Jun 15, 2026
Coverage: 246 bars · Jun 23, 2025 → Jun 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Vir Biotechnology, Inc. (VIR) is a Healthcare stock with a market cap of $1.61B and listed on NASDAQ. The stock last traded around $9.16 and up 70.5% across the available one-year price window (Jun 23, 2025 → Jun 15, 2026). Baseline metrics include revenue growth of -7.6%, EPS growth of +17.5%, a dividend yield of 0.0%. What stands out right now is revenue -7.6%, EPS +17.5%, free cash flow +12.6% with operating margin -682.7% and ROIC -50.9%. Valuation already assumes a fairly strong business story at price/sales 23.5. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines VIR price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
VIR
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
VIR Max Drawdown
-27.82%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for VIR and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$1.1B
-32.2% YoY
FY Net Income
$528.6M
+2.5% YoY
Free Cash Flow
-$69.4M
-104.4% YoY
Revenue Growth
-7.6%
EPS Growth
+17.5%
Gross Margin
100.0%
Net Margin
-638.9%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 69M | 74M | 86M | 1.6B | 1.1B |
| Gross Profit | 57M | -404M | -487M | 995M | 582M |
| Operating Income | -468M | -587M | -684M | 833M | 421M |
| EBITDA | -426M | -509M | -642M | 840M | 427M |
| Net Income | -438M | -522M | -615M | 516M | 529M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 234M | 223M | 242M | 849M | 348M |
| Total Assets | 1.0B | 1.4B | 1.9B | 2.8B | 2.0B |
| Total Liabilities | 238M | 248M | 329M | 724M | 522M |
| Shareholder Equity | 765M | 1.2B | 1.6B | 2.1B | 1.4B |
| Total Debt | 187M | 98M | 125M | 128M | 137M |
| Net Debt | -47M | -125M | -117M | -721M | -210M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
48M
-102.9% YoY
Capital Expenditures
22M
+67.9% YoY
Free Cash Flow
69M
-104.4% YoY
Key ratios
Gross Margin
100.0%
Operating Margin
-682.7%
Net Margin
-638.9%
ROE
-49.3%
Debt / Equity
0.24x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.